Pharyngosept® (Faringosept®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAmbazonAmbazon
Similar drugsTo uncover
  • Pharyngosept®
    pills locally inwards 
    Ranbaxy Laboratories Limited     India
  • Pharyngosept®
    pills locally inwards 
    Ranbaxy Laboratories Limited     India
    • Dosage form: & nbsplemon-dissolving tablets
    Composition:

    Each tablet for resorption with a taste of lemon contains:

    Active substance: Ambazone monohydrate 10 mg

    Excipients: sucrose 745 mg, lactose monohydrate 150 mg. cocoa beans powder 25 mg, povidone K-30 50 mg, lemon flavor 10 mg, stearic acid 10 mg.

    Description:

    Round, flat-cylindrical, beveled to the edge of the tablet, brown with intact edges and engraved "E" on one side. Light and dark inclusions are allowed.

    Pharmacotherapeutic group:Antiseptic
    ATX: & nbsp

    R.02.A.A.01   Ambazon

    Pharmacodynamics:Has a bacteriostatic effect. Has a local antimicrobial effect. Active with a number of gram-positive microorganisms (Streptococcus haemolyticus, Streptococcus viridans, Pneumococcus). On the microflora of the intestine is not affected.
    Pharmacokinetics:

    The optimal therapeutic concentration in saliva is achieved on the 3-4th day of taking the drug at a dose of 0.03-0.05 g / day.

    Indications:

    Symptomatic treatment of infectious and inflammatory diseases of the oral cavity and pharynx: tonsillitis, gingivitis, stomatitis, pharyngitis.

    Contraindications:

    Hypersensitivity to Ambazone and other components of the drug; lactose intolerance, fructose, sugarase / isomaltase deficiency, glucose-galactose malabsorption, lactase deficiency; children under 3 years.

    Pregnancy and lactation:

    Pregnant and lactating women should consult a doctor before applying preparation.

    In pregnancy and during breastfeeding apply only if the intended benefit to the mother exceeds the potential risk to the fetus and the baby.
    Dosing and Administration:

    Locally. Tablets should be resorbed until completely dissolved (15-30 minutes after eating). After using the tablets, you should abstain for 3 hours from drinking and eating.

    Adults: 4-5 tablets (0.04-0.05 g) per day.

    Children: 3 to 7 years 3 tablets (0.03 grams) per day.

    The course of treatment is 3-4 days.

    Side effects:

    Allergic reactions to the components of the drug, skin rash.

    If any of the side effects indicated in the manual are aggravated, or if you notice any other side effects indicated in the instructions, tell your doctor.

    Overdose:

    Cases of an overdose of ambazone are unknown. There is no antidote.Possible overdose can lead to symptoms of discomfort from the gastrointestinal tract. When using an excessive dose, it is recommended to rinse the stomach.

    Interaction:

    Clinically significant interactions with other drugs have not been identified.

    Special instructions:

    Do not use the drug in the presence of increased individual sensitivity to any component that is part of the drug.

    The drug is not recommended for patients with hereditary intolerance to sucrose and lactose.

    The increase in dose does not have a greater clinical effect.

    If symptoms persist or if there is an increase in body temperature or headache, consult a doctor.

    Effect on the ability to drive transp. cf. and fur:The drug does not affect the ability to drive vehicles and mechanisms, as well as to engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:

    Tablets for resorption with a taste of lemon 10 mg.

    Packaging:

    10 tablets per blister of aluminum foil and dark transparent PVC-PE-PVDC film.

    For 10 tablets in a blister of aluminum foil and colorless transparent PVC-PE-PVDC film.

    For 1 or 2 blisters together with instructions for use in a cardboard box.

    Storage conditions:

    In the original packaging at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    The drug can not be used later than the date indicated on the packaging.

    Terms of leave from pharmacies:Without recipe
    Registration number:П N015365 / 01
    Date of registration:17.05.2010
    The owner of the registration certificate:Ranbaxy Laboratories LimitedRanbaxy Laboratories Limited India
    Manufacturer: & nbsp
    Representation: & nbspRABBAYS LABORATORY LIMITEDRABBAYS LABORATORY LIMITED
    Information update date: & nbsp28.08.2015
    Illustrated instructions
      Instructions
      Up